Efavaleukin Alfa (AMG 592): A Comprehensive Analysis of a Treg-Selective IL-2 Mutein from Bench to Clinical Discontinuation

Section I: Executive Summary

Efavaleukin alfa (also known as AMG 592) represents a sophisticated example of rational drug design in modern biotechnology, developed by Amgen as a potential therapy for a range of autoimmune and inflammatory diseases. The molecule is a recombinant fusion protein, precisely engineered to address a fundamental challenge in immunology: how to leverage the therapeutic, immunosuppressive properties of Interleukin-2 (IL-2) without invoking its potent, pro-inflammatory effects. This was achieved by creating an IL-2 "mutein" with specific amino acid mutations to decrease its affinity for the intermediate-affinity IL-2 receptor subunit (IL-2Rβ) and increase its dependence on the high-affinity subunit (IL-2Rα, or CD25). This design preferentially targets regulatory T cells (Tregs), which constitutively express high levels of CD25 and are critical for maintaining immune tolerance. By fusing this IL-2 mutein to an immunoglobulin G1 (IgG1) Fc fragment, Amgen also engineered a significantly extended pharmacokinetic half-life, allowing for more convenient dosing regimens.

The preclinical and early-phase clinical development of Efavaleukin alfa was a resounding success from a pharmacological perspective. In vitro, in vivo non-human primate, and Phase 1 human studies consistently demonstrated that the drug achieved its design goals with remarkable precision. It induced robust, dose-dependent, and highly selective expansion of functional Tregs with a favorable safety profile, characterized primarily by minor injection site reactions and a notable absence of the pro-inflammatory cytokine release associated with traditional IL-2 therapy. This strong pharmacodynamic effect, correcting a key cellular deficit implicated in autoimmunity, provided a compelling rationale to advance the molecule into mid- and late-stage clinical trials across a broad spectrum of diseases.

Despite this promising foundation, the development program for Efavaleukin alfa ultimately ended in a series of discontinuations. Phase 2b clinical trials in Systemic Lupus Erythematosus (SLE) and Ulcerative Colitis (UC) were terminated for futility, indicating the drug was unlikely to meet its primary efficacy endpoints. Similarly, earlier-stage programs in steroid-refractory chronic Graft-Versus-Host Disease (cGVHD)—for which the drug had received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA)—and Rheumatoid Arthritis (RA) were also halted due to a lack of convincing therapeutic benefit.

This report provides a comprehensive analysis of the Efavaleukin alfa program, from its scientific rationale and molecular engineering through its full clinical development history and strategic implications. The failure of Efavaleukin alfa, a molecule that performed exactly as designed at a pharmacodynamic level, offers critical lessons. It underscores the profound gap that can exist between modulating a specific biological pathway and altering the course of complex, established human diseases. It highlights the persistent challenges of clinical development in heterogeneous autoimmune conditions, particularly the high placebo/standard-of-care response rates that can obscure true efficacy signals. Furthermore, the program serves as a case study in modern R&D management, where the use of innovative adaptive trial designs enabled Amgen to make efficient "fail fast" decisions, manage risk, and strategically reallocate resources within its inflammation portfolio. The story of Efavaleukin alfa is a cautionary tale but also an invaluable source of knowledge for the future development of selective immunomodulatory therapies.

Section II: Scientific Rationale and Molecular Profile

2.1. The IL-2/Treg Axis: A Critical Fulcrum in Immune Homeostasis

The scientific foundation for Efavaleukin alfa is rooted in the complex and dichotomous biology of Interleukin-2 (IL-2). Historically, IL-2 was identified as a T-cell growth factor and harnessed therapeutically for its immunostimulatory properties, leading to its approval as a high-dose treatment for certain cancers like metastatic renal cell carcinoma and melanoma.[1] However, this understanding evolved dramatically with the discovery of its non-redundant and essential role in maintaining immune tolerance through its effects on regulatory T cells (Tregs).[2] This dual functionality presented a significant therapeutic challenge: selectively amplifying the immunosuppressive arm of IL-2 signaling while minimizing its pro-inflammatory, effector-stimulating activities.

Tregs are a specialized subpopulation of T cells that are critical for maintaining peripheral tolerance, preventing autoimmune diseases, and limiting chronic inflammatory responses.[7] A defining characteristic of Tregs is their unique dependence on IL-2 for their development in the thymus and for their survival, fitness, and suppressive function in the periphery.[5] Unlike conventional T cells (Tcons), Tregs do not produce IL-2 upon activation and are therefore reliant on scavenging it from the local microenvironment.[6] This has led to the concept of Tregs acting as an "IL-2 sink," where they effectively sequester available IL-2, thereby limiting the proliferation of potentially auto-reactive effector T cells while simultaneously promoting their own suppressive functions.[6]

The ability of IL-2 to mediate these opposing effects is governed by the differential expression of its receptor components on various immune cell populations. The IL-2 receptor (IL-2R) can exist in three forms with varying affinities for IL-2. The high-affinity heterotrimeric receptor, composed of the IL-2Rα (CD25), IL-2Rβ (CD122), and common gamma (γc, CD132) chains, is constitutively expressed at high levels on Tregs.[3] In contrast, effector T cells and Natural Killer (NK) cells primarily express the intermediate-affinity heterodimeric receptor, consisting of the IL-2Rβ and γc chains, only upregulating CD25 transiently upon activation.[3] The low-affinity receptor consists of the CD25 subunit alone and is incapable of signal transduction.[6] This differential receptor expression provides the scientific cornerstone for designing therapies that can selectively target Tregs.

The rationale for a Treg-selective therapy is strongly supported by the pathophysiology of numerous autoimmune diseases. Conditions such as Systemic Lupus Erythematosus (SLE) and chronic Graft-Versus-Host Disease (cGVHD) are characterized by quantitative and/or qualitative defects in the Treg population and disruptions in the IL-2 signaling pathway, which correlate with disease activity.[4] Consequently, restoring this axis by selectively expanding the Treg population emerged as a highly rational and promising therapeutic strategy to re-establish immune homeostasis.

2.2. Molecular Engineering of Efavaleukin Alfa (AMG 592)

Efavaleukin alfa is a biotech drug classified as a recombinant fusion protein, meticulously engineered by Amgen to exploit the biology of the IL-2/Treg axis.[9] The molecule is a homodimer, with each monomeric chain consisting of two key components joined by a flexible linker: a modified human IL-2 molecule (an "IL-2 mutein") and a human immunoglobulin G1 (IgG1) Fc fragment.[9] The IL-2 mutein is fused to the C-terminus of the Fc domain via a Glycine-Serine linker (

G4​S), and the entire protein is produced in Chinese Hamster Ovary (CHO) cells.[14]

The central innovation of Efavaleukin alfa lies in its IL-2 mutein component.[5] Through protein engineering, specific amino acid substitutions were introduced into the wild-type IL-2 sequence. Based on the full amino acid sequence data, these mutations are V322K and C356A (relative to the full fusion protein sequence), which correspond to standard IL-2 numbering conventions of V91K and C145A.[1] The purpose of these mutations was to fundamentally alter the receptor binding profile of the cytokine. Specifically, the engineering was designed to significantly decrease the binding affinity of the mutein for the IL-2Rβ subunit (CD122) while preserving or increasing its dependence on the IL-2Rα subunit (CD25) for high-affinity binding.[5] This re-engineering biases the molecule's activity towards the CD25-rich, high-affinity IL-2Rαβγc complex found on Tregs, thereby promoting their selective stimulation over conventional T cells and NK cells, which are more dependent on signaling through the intermediate-affinity IL-2Rβγc complex.[9]

The second key engineering feature is the fusion to an IgG1 Fc fragment. This is a well-established biopharmaceutical strategy to improve the pharmacokinetic properties of smaller proteins.[5] Native IL-2 has a very short in-vivo half-life, necessitating frequent and high-dose administration that contributes to its toxicity and narrow therapeutic window.[1] By fusing the IL-2 mutein to the much larger Fc domain, Efavaleukin alfa leverages the neonatal Fc receptor (FcRn) recycling pathway, which dramatically extends its circulating half-life.[5] This allows for substantially less frequent dosing regimens, such as the every-two-week (Q2W) schedule tested in clinical trials, improving its potential as a chronic therapy.[23] The full sequence also reveals variants within the IgG1 Fc domain itself (N77G, D136E, L138M), which are typically introduced to modulate Fc receptor binding, either to silence effector functions or to further fine-tune the molecule's half-life.[16]

The final product is a glycosylated, dimeric fusion protein with an estimated average molecular weight of approximately 82.2 kDa.[16] This sophisticated design positions Efavaleukin alfa as a second-generation IL-2 therapeutic, moving beyond the simple dose modulation of first-generation agents like aldesleukin to a highly specific, rationally engineered biologic intended to deliver a precise immunological effect with an improved safety and dosing profile.

2.3. Mechanism of Action: Selective Treg Stimulation

The mechanism of action for Efavaleukin alfa is classified as a regulatory T-lymphocyte stimulant or, more broadly, an IL-2 agonist.[13] Its therapeutic activity is a direct consequence of its engineered molecular properties. By preferentially binding to the high-affinity IL-2 receptor (IL-2Rαβγc), which is abundantly and constitutively expressed on the surface of Tregs, Efavaleukin alfa achieves selective activation of this cell population.[7]

Upon binding, the drug leads to increased cell surface retention and sustained downstream intracellular signaling, primarily through the phosphorylation of Signal Transducer and Activator of Transcription 5 (STAT5), which is the dominant IL-2 signaling pathway in Tregs.[5] This sustained signaling cascade promotes the proliferation, survival, and functional fitness of the Treg population.

The central therapeutic hypothesis is that this selective and prolonged expansion of functional Tregs can restore immune homeostasis in the context of autoimmune disease.[20] By bolstering the body's own regulatory mechanisms, the therapy aims to suppress the pathogenic, self-reactive immune responses that drive diseases like SLE and cGVHD. Critically, because of its reduced affinity for the IL-2Rβ subunit, Efavaleukin alfa was designed to achieve this Treg expansion without causing significant activation or proliferation of pro-inflammatory effector T cells and NK cells, thereby avoiding the broad immunostimulation and associated toxicities of high-dose IL-2 therapy.[5]

Characteristic	Description	Supporting Sources
Drug Name	Efavaleukin alfa	14
Alternative Names	AMG 592; IL-2 mutein Fc fusion protein	13
DrugBank ID	DB16149	14
CAS Number	2049067-94-7	16
Originator	Amgen	13
Type	Biotech, Recombinant Fusion Protein	13
Structure	Homodimer of a human IL-2 mutein fused to the C-terminus of a human IgG1 Fc fragment via a flexible G4S linker.	9
Key Mutations	IL-2 Mutein: V91K, C145A (standard numbering); IgG1 Fc: N77G, D136E, L138M	1
Molecular Weight	~82.2 kDa (average, glycosylated dimer)	16
Mechanism of Action	Regulatory T-lymphocyte stimulant; IL-2 agonist with engineered selectivity for the high-affinity IL-2Rα (CD25) subunit, leading to preferential expansion of Tregs.	9

Section III: Preclinical and Early Phase Pharmacological Profile

The progression of Efavaleukin alfa from concept to clinical investigation was underpinned by a robust body of preclinical and early-phase clinical data that successfully validated its intended design. These initial studies demonstrated with remarkable consistency that the engineered molecule could selectively expand Tregs with an improved safety and pharmacokinetic profile compared to conventional IL-2. This early success, however, ultimately set the stage for a significant scientific paradox when the potent pharmacodynamic effects failed to translate into clinical efficacy in later-stage trials.

3.1. Preclinical Characterization: Validating the Design

The preclinical development program for Efavaleukin alfa provided the essential in vitro and in vivo proof-of-concept required to justify human testing. The studies were designed to directly assess whether the molecular engineering had achieved the dual goals of Treg selectivity and improved safety.

In vitro studies using primary human peripheral blood mononuclear cell (PBMC) cultures confirmed the drug's selectivity at a cellular level. Compared to aldesleukin (recombinant human IL-2), Efavaleukin alfa induced a significantly more selective response in Tregs, as measured by key signaling events like the phosphorylation of STAT5 (pSTAT5) and by cellular proliferation assays.[22] Furthermore, these cultures demonstrated that Efavaleukin alfa stimulation resulted in markedly lower production of pro-inflammatory cytokines such as IL-6, TNFα, and IFN-γ, confirming that the desired immunoregulatory effect was uncoupled from broad, pro-inflammatory activation.[22]

These promising in vitro findings were corroborated in non-human primate models. In studies with cynomolgus monkeys, Efavaleukin alfa produced a dose-dependent expansion of FoxP3+ Tregs. Critically, this expansion occurred without the concomitant increases in body temperature and C-reactive protein (CRP) that were observed in monkeys treated with aldesleukin.[22] This was a key finding, suggesting that Efavaleukin alfa possessed a wider therapeutic margin and a more favorable in vivo safety profile, directly addressing one of the major limitations of existing IL-2 therapies. Collectively, these preclinical data provided strong evidence that the drug's design was sound and that it was ready for evaluation in humans.[27]

3.2. Phase 1 First-in-Human (FIH) Studies in Healthy Volunteers

The first-in-human clinical trials of Efavaleukin alfa largely recapitulated the successful preclinical results, confirming the drug's intended pharmacological profile in humans. Multiple Phase 1 studies were conducted, including a key study (NCT04987333) designed to evaluate safety and pharmacokinetics in healthy Chinese, Japanese, and Caucasian subjects to support global development.[28]

Across these studies, Efavaleukin alfa was generally safe and well-tolerated. In single ascending dose trials, the most common adverse event was mild (Grade 1), painless erythema at or near the subcutaneous injection site, which typically resolved without intervention. Importantly, there were no serious adverse events, and consistent with the preclinical data, no clinically significant increases in systemic pro-inflammatory cytokines were detected.[22]

The pharmacokinetic (PK) profile confirmed the benefit of the Fc fusion design. Serum exposure increased in a dose-proportional manner, and the drug exhibited a terminal half-life of 18 to 30 hours.[12] This represents a substantial extension compared to the very short half-life of native IL-2, validating the engineering strategy to create a molecule suitable for less frequent dosing.

The pharmacodynamic (PD) data provided the most compelling evidence of the drug's success. Efavaleukin alfa induced a robust, dose-dependent, and highly selective expansion of Tregs in all treated individuals.[23] The peak expansion of FoxP3+ Tregs was observed approximately 8 days after a single dose, and the effect was remarkably sustained, with Treg counts remaining elevated for up to 29 to 42 days at the higher doses tested.[12] This long-lasting biological effect, driven by a much shorter PK half-life, suggested that the drug acted as a potent trigger for a durable biological response, a highly desirable therapeutic property. The selectivity of this effect was a key confirmation of the mechanism of action; there was no directional change in NK cell numbers and only minimal, non-dose-dependent increases in conventional T cells.[23] The expanded Tregs were also phenotypically characterized as functional, showing increased expression of the master regulator FoxP3 and the high-affinity receptor subunit CD25. Furthermore, the expansion included recent thymic emigrant (RTE) Tregs, indicating that the drug was stimulating the proliferation of newly produced, naive Tregs in addition to memory populations.[12]

Trial Identifier	Phase	Indication	Key Objective(s)	Status	Stated Reason for Termination
NCT04680637	Phase 2b	Systemic Lupus Erythematosus (SLE)	Evaluate efficacy and safety in active SLE with inadequate response to standard of care.	Terminated	Futility
NCT03422627	Phase 1b/2	Chronic Graft-vs-Host Disease (cGVHD)	Evaluate safety, tolerability, and efficacy in steroid-refractory cGVHD.	Terminated	Not specified (Phase 2 not initiated)
NCT04987307	Phase 2	Ulcerative Colitis (UC)	Evaluate induction of clinical remission in moderately to severely active UC.	Terminated	Futility
NCT05672199	Phase 2	Ulcerative Colitis (UC)	Long-term extension study for NCT04987307.	Terminated	Parent study terminated
NCT03410056	Phase 1	Rheumatoid Arthritis (RA)	Evaluate safety and efficacy in active RA.	Terminated	Insufficient therapeutic benefit
NCT03451422	Phase 1b	Systemic Lupus Erythematosus (SLE)	Evaluate safety, tolerability, PK/PD, and immunogenicity in SLE patients.	Completed	N/A
NCT04987333	Phase 1	Inflammation (Healthy Volunteers)	Evaluate safety and PK in healthy Chinese, Japanese, and Caucasian subjects.	Completed	N/A

Section IV: The Clinical Development Program in Systemic Lupus Erythematosus (SLE)

The development of Efavaleukin alfa for Systemic Lupus Erythematosus (SLE) was the centerpiece of Amgen's clinical program for the drug. Supported by a strong biological rationale and highly encouraging Phase 1 data, the SLE program was pursued with an ambitious and innovative clinical trial design. Its ultimate discontinuation for futility serves as a critical case study on the formidable challenges of translating a targeted pharmacodynamic effect into a meaningful clinical outcome in a complex, heterogeneous autoimmune disease.

4.1. Rationale and Phase 1b Study (NCT03451422)

The rationale for targeting the IL-2/Treg axis in SLE is compelling. The disease is characterized by well-documented defects in both the number and suppressive function of Tregs, and these abnormalities have been shown to correlate with disease activity, suggesting they are integral to its pathogenesis.[4] The therapeutic hypothesis was that by selectively expanding and restoring the function of the Treg population, Efavaleukin alfa could correct this core immunological imbalance and thereby ameliorate the disease.

A Phase 1b multiple ascending dose study (NCT03451422) was conducted in 35 patients with SLE to bridge the findings from healthy volunteers to a patient population.[29] The results from this study were highly positive and confirmed the drug's mechanism of action in the target disease. Multiple subcutaneous doses administered every week or every two weeks were found to be safe and well-tolerated.[12] The pharmacodynamic effects were consistent and robust, showing a selective and prolonged expansion of Tregs. At the highest bi-weekly dose, a mean peak increase in Foxp3+ Tregs of 17.4-fold above baseline was observed.[12] The study also demonstrated expansion of key functional Treg subsets, including CD25bright Tregs and recent thymic emigrants.[7]

A particularly significant finding from this study was the observation that Efavaleukin alfa treatment restored the expression of CD25 on Tregs in SLE patients to levels comparable to those seen in healthy controls, without affecting CD25 expression on conventional T cells.[7] Since lower CD25 expression on Tregs is a known defect in SLE, this finding suggested that the drug was not only expanding the Treg population but was also correcting a key disease-associated biomarker. These strong results provided the confidence to proceed to a large, pivotal Phase 2b study.

4.2. The VIOLET Trial (Phase 2b, NCT04680637): An Ambitious Design Meets a Challenging Disease

The VIOLET trial was a large-scale, Phase 2b, dose-ranging, double-blind, placebo-controlled study designed to definitively evaluate the efficacy and safety of Efavaleukin alfa in patients with active SLE who had an inadequate response to standard-of-care therapies.[32] The design of this trial reflected a sophisticated understanding of the well-known challenges inherent in SLE clinical research, namely high placebo response rates, significant patient and disease heterogeneity, and the complexity of measuring clinical improvement.[35]

To navigate these challenges, Amgen implemented a Bayesian adaptive trial design.[35] This innovative approach incorporated several key features to improve trial efficiency and the probability of obtaining a clear result. First, it included prospectively planned interim assessments for futility, allowing the trial to be stopped early if the investigational therapy was unlikely to demonstrate a meaningful benefit.[36] Second, it utilized response-adaptive randomization (RAR), a method that allows the randomization ratios to shift during the trial based on accumulating data, allocating more patients to the more efficacious dose arms while keeping the placebo allocation constant.[36] This strategy can increase the statistical power to estimate the treatment effect and generate more data for the optimal dose(s).

The novelty and rigor of this trial design were recognized by the U.S. Food and Drug Administration (FDA), which selected the VIOLET protocol for its Complex Innovative Trial Designs (CID) Pilot Program.[26] This signaled regulatory support for the use of such advanced methodologies to accelerate drug development and overcome the historical difficulties in the SLE field.

4.3. Discontinuation for Futility: Unpacking the Failure

In a significant setback for the program, Amgen announced in its Q1 2023 earnings report in April 2023 that it was discontinuing the Phase 2b VIOLET study of Efavaleukin alfa in SLE.[39] The reason cited was "futility," which, in the context of its adaptive design, meant that an interim analysis concluded the drug was highly unlikely to meet its primary efficacy endpoints upon completion of the trial.

This outcome presented a profound scientific question. The drug had unequivocally demonstrated its ability to achieve its intended biological effect—the selective and sustained expansion of Tregs, even correcting a disease-associated biomarker in SLE patients. Yet, this potent pharmacodynamic activity did not translate into a measurable clinical benefit that was superior to that of placebo plus standard of care. This points to a fundamental disconnect between the targeted mechanism and the complex, established pathology of the disease in the trial population.

Several factors could explain this translation gap. The magnitude of immune suppression afforded by Treg expansion, while statistically robust, may have been biologically insufficient to overcome the multiple, redundant inflammatory pathways driving active SLE. It is also possible that the expanded Tregs, while numerous, were functionally impaired within the hostile inflammatory microenvironment of SLE tissues, or that they did not traffic effectively to the sites of pathology. Finally, the inherent challenges of the indication itself cannot be discounted. The high response rate often seen in patients receiving placebo plus optimized standard-of-care therapy in SLE trials creates a very high bar for demonstrating the incremental benefit of a new agent, a problem that even a sophisticated adaptive design could not overcome in this case.[35] The failure of Efavaleukin alfa in SLE suggests that simply "more Tregs" may not be a powerful enough intervention for this complex disease.

Section V: Investigation in Chronic Graft-Versus-Host Disease (cGVHD)

In parallel with its efforts in SLE, Amgen pursued the development of Efavaleukin alfa for chronic Graft-Versus-Host Disease (cGVHD), an indication with a strong biological rationale and significant unmet medical need. The program received regulatory support in the form of an Orphan Drug Designation. However, like the SLE program, the cGVHD investigation was ultimately terminated, reinforcing the conclusion that the drug's potent pharmacodynamic effect was not translating into clinical benefit.

5.1. Rationale and Trial Design (NCT03422627)

Chronic GVHD is a frequent and severe complication following allogeneic hematopoietic cell transplantation (HCT), where immune cells from the donor recognize the recipient's tissues as foreign and mount an attack.[41] A key element in the pathophysiology of cGVHD is a profound deficiency in the number and function of regulatory T cells, which are essential for establishing and maintaining tolerance between the donor graft and the recipient.[10] This makes the targeted expansion of Tregs with a therapy like Efavaleukin alfa a highly logical and direct therapeutic strategy.

To test this hypothesis, Amgen initiated a Phase 1b/2 open-label clinical trial (NCT03422627).[14] The trial was designed to enroll adult subjects with moderate to severe steroid-refractory cGVHD, a patient population with limited treatment options and poor prognosis.[42] The study was structured in two parts: a Phase 1b dose-escalation portion to evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics of multiple ascending doses of Efavaleukin alfa, followed by a planned Phase 2 portion to evaluate efficacy, with the primary endpoint being the Overall Response Rate (ORR) at 16 weeks based on the 2014 NIH Consensus Criteria.[42]

5.2. Regulatory Context: Orphan Drug Designation

Recognizing the severity of cGVHD and the lack of adequate therapies, the U.S. Food and Drug Administration (FDA) granted Efavaleukin alfa Orphan Drug Designation for the treatment of Graft-Versus-Host-Disease.[16] This designation is granted to drugs intended to treat rare diseases or conditions affecting fewer than 200,000 people in the United States. The designation provides the sponsor with significant incentives to facilitate drug development, including tax credits for clinical trials, waiver of prescription drug user fees, and, most importantly, a potential seven years of market exclusivity upon approval.[46] Securing this designation underscored Amgen's commitment to the cGVHD program and highlighted the potential commercial viability of the drug in this niche but high-need indication.

5.3. Early Termination of the Trial

Despite the strong rationale and regulatory incentives, the cGVHD trial was terminated early.[9] According to the trial record, the Phase 2 portion of the study was never conducted.[42] While the specific clinical results from the Phase 1b dose-escalation cohorts are not detailed in the available documentation, the decision to halt the entire program before even initiating the efficacy-focused Phase 2 part is a strong negative signal. It implies that the open-label data generated in Phase 1b were not sufficiently promising to warrant further investment.

This early termination in a second major indication was a critical turning point for the Efavaleukin alfa program. Unlike the double-blind, placebo-controlled SLE trial, the failure in the open-label cGVHD study could not be attributed to a high placebo response. The pathophysiology of cGVHD is also arguably more directly linked to a Treg deficit than the multifactorial pathology of SLE. The failure in this context strongly suggested that the issue was not with the trial design or the specific disease, but rather with the fundamental therapeutic efficacy of the drug's mechanism. The inability to demonstrate a convincing signal of activity in an open-label setting in a disease so clearly linked to Treg biology reinforced the emerging conclusion that selective Treg expansion alone was not a sufficiently potent intervention to reverse established immunopathology.

Section VI: Evaluation in Ulcerative Colitis (UC) and Rheumatoid Arthritis (RA)

To explore the full potential of its Treg-selective mechanism, Amgen's clinical development plan for Efavaleukin alfa extended beyond SLE and cGVHD to include two other major inflammatory conditions: Ulcerative Colitis (UC) and Rheumatoid Arthritis (RA). The outcomes in these indications mirrored the others, with both programs being terminated due to a lack of clinical efficacy. This pattern of failure across four distinct diseases solidified the conclusion that the drug's elegant biological mechanism lacked the necessary potency to be a viable therapy.

6.1. The Ulcerative Colitis Program (NCT04987307, NCT05672199)

The rationale for investigating Efavaleukin alfa in UC was based on evidence that a loss of immune homeostasis, including defects in the Treg population, is a contributing factor to the chronic mucosal inflammation that characterizes the disease.[48] Amgen launched a Phase 2 program to evaluate the drug in patients with moderately to severely active UC who had failed or were intolerant to conventional therapies, biologics, or targeted small molecules.[48]

The core of the program was a Phase 2, dose-finding, randomized, double-blind, placebo-controlled study (NCT04987307) designed to assess the drug's ability to induce clinical remission over a 12-week induction period.[50] A long-term extension study (NCT05672199) was also established to evaluate safety and efficacy over a longer duration for patients completing the parent study.[9]

In October 2024, it was reported that Amgen had halted the Phase 2b study in UC after it met a prespecified futility threshold at an interim analysis.[56] The company emphasized that the termination was not due to safety concerns but rather a lack of efficacy.[56] This outcome in a third major indication further weakened the case for the drug's therapeutic potential. While the overall safety profile was acceptable, a separate Phase 1 study in healthy volunteers (NCT04987333) had been placed on a temporary hold due to adverse events occurring after day 4 of dosing, which necessitated a protocol amendment to increase monitoring.[57] This suggests that while the drug did not have overt, program-ending toxicity, its tolerability required careful management.

6.2. The Rheumatoid Arthritis Program (NCT03410056)

Rheumatoid Arthritis (RA), a classic systemic autoimmune disease where Treg dysfunction is a well-established pathogenic feature, was another logical indication for Efavaleukin alfa. Amgen initiated a Phase 1 clinical trial (NCT03410056) to evaluate the safety and efficacy of the drug in patients with active RA.[9]

This program was the first among the patient trials to show signs of clinical futility. The trial was terminated early, with Amgen officially stating the reason as "insufficient therapeutic benefit" for the combination of Efavaleukin alfa with standard-of-care therapy in the studied population.[23] This early stop, even at the Phase 1 stage in patients, provided the initial evidence that the robust Treg expansion observed in healthy volunteers might not be sufficient to impact clinical disease activity in patients with established, chronic inflammation.

The cumulative evidence from these four distinct clinical programs painted a clear and consistent picture. Despite being tested in a wide range of autoimmune and inflammatory conditions—systemic (SLE), allo-immune (cGVHD), mucosal (UC), and joint-focused (RA)—Efavaleukin alfa failed to demonstrate meaningful clinical efficacy in any of them. This cross-indication failure makes it highly unlikely that the issues were related to the specific design, endpoints, or patient population of any single trial. The common denominator was the drug itself and its mechanism of action, leading to the inescapable conclusion that selective Treg expansion via this IL-2 mutein is not a sufficiently powerful intervention to meaningfully alter the course of these complex diseases.

Section VII: Integrated Safety and Tolerability Analysis

A key objective in the design of Efavaleukin alfa was to create a therapy that could deliver the immunoregulatory benefits of IL-2 signaling without the significant toxicities associated with high-dose IL-2. The clinical data gathered across the entire development program—spanning Phase 1 studies in healthy volunteers and Phase 1/2 studies in patients with SLE, cGVHD, RA, and UC—indicate that this safety objective was largely achieved. While the drug ultimately failed on efficacy, its safety and tolerability profile was generally favorable and consistent with its engineered mechanism.

Across all studies, Efavaleukin alfa was consistently described as being well-tolerated.[5] The most frequently reported treatment-emergent adverse events (TEAEs) were non-serious and of mild-to-moderate (Grade 1-2) severity. The most common of these were local injection site reactions, such as painless erythema, which typically resolved without medical intervention.[5]

Serious adverse events (SAEs) and dose-limiting toxicities (DLTs) were infrequent. In the Phase 1b study in SLE patients, no DLTs were reported.[12] Two SAEs were observed in the efavaleukin alfa-treated group: one event of syncope (Grade 3), which was not considered treatment-related, and one case of eosinophilia (Grade 2), which was considered related to treatment.[5] Eosinophilia is a known pharmacodynamic effect of IL-2 signaling, as IL-2 can promote the activation of Type 2 innate lymphoid cells (ILC2s) which in turn secrete IL-5, a key driver of eosinophil expansion.[6]

Analysis of the highest dose levels tested in the SLE study revealed low-level increases in the numbers of conventional CD4+ T cells (peak 2.3-fold), CD8+ T cells (peak 2.1-fold), and NK cells (peak 2.9-fold).[5] This suggested a potential plateau in Treg expansion and a slight loss of selectivity at the upper end of the dose range, leading investigators to conclude that the highest tested dose was likely outside the optimal therapeutic window and should not be advanced into Phase 2 studies.[5] Additionally, a Phase 1 study in healthy volunteers (NCT04987333) was temporarily paused to allow for evaluation of emerging safety data and a protocol amendment to enhance monitoring, after adverse events were reported in subjects after day 4 post-dosing.[57] These instances indicate that while the drug was generally safe, there were tolerability signals, particularly at higher exposures, that required careful dose selection and patient monitoring.

Crucially, the molecular engineering of Efavaleukin alfa was successful in avoiding the most significant toxicities of high-dose IL-2. Clinical studies consistently showed a lack of pro-inflammatory cytokine release, with no increases in serum levels of IL-6, TNFα, or IFN-γ above the limits of detection.[23] This confirmed that the drug's biased binding profile had effectively uncoupled the desired Treg stimulation from the broad, systemic inflammation that causes conditions like vascular leak syndrome. The fact that Amgen explicitly stated the terminations of the large Phase 2 trials in SLE and UC were due to futility and not for safety concerns further underscores that the drug's safety profile was acceptable.[56] Ultimately, however, a safe but ineffective drug holds no clinical value. The successful safety profile makes the consistent lack of efficacy across multiple indications all the more scientifically significant, pointing not to a flawed molecule, but to a flawed therapeutic hypothesis.

Section VIII: Strategic and Scientific Conclusion: The Promise and Peril of Selective Immunomodulation

The development and subsequent discontinuation of Efavaleukin alfa offers a compelling and cautionary narrative in the field of biopharmaceutical R&D. It represents the story of a "good" drug—one that was elegantly designed, precisely engineered, and pharmacologically successful—that ultimately failed to deliver clinical benefit. The program's trajectory provides invaluable lessons about the gap between biological mechanism and clinical reality, the challenges of drug development in complex diseases, and the execution of a disciplined, modern R&D strategy.

8.1. Synthesis of Failure: Why Did a "Good" Drug Fail?

Efavaleukin alfa succeeded on nearly every metric leading up to pivotal efficacy testing. Its molecular engineering successfully biased IL-2 receptor binding to favor Tregs, and its Fc fusion extended its half-life to allow for a convenient dosing schedule. Preclinical and Phase 1 studies confirmed this with remarkable precision: the drug was well-tolerated, avoided pro-inflammatory signals, and induced a robust, selective, and sustained expansion of the target Treg population in both healthy subjects and patients. It even corrected a disease-associated biomarker in SLE patients by restoring Treg CD25 expression to healthy levels.[7]

The failure, therefore, was not in the drug's design or its pharmacodynamic effect, but in the translation of that effect into a clinical outcome. The core conclusion from the consistent pattern of futility across SLE, cGVHD, UC, and RA is that for these complex, established autoimmune diseases, simply increasing the number of circulating Tregs is an insufficient therapeutic intervention. This suggests several possibilities: the magnitude of the Treg expansion, while statistically significant, may not have been sufficient to overcome the momentum of entrenched pathogenic inflammation; the expanded Tregs may not have trafficked effectively to the relevant tissue sites; or the hostile inflammatory microenvironment within those tissues may have rendered the newly expanded Tregs functionally impotent. The failure of Efavaleukin alfa forces a re-evaluation of the therapeutic hypothesis, suggesting that successful immunomodulation in these diseases may require more than just boosting the numbers of a single regulatory cell type.

8.2. Broader Implications for Autoimmune Drug Development

The story of Efavaleukin alfa holds several important implications for the broader field. First, it vividly illustrates the challenge of disease heterogeneity. A single, targeted mechanism may only be effective in a specific subset of patients whose disease is primarily driven by the targeted pathway. Without robust biomarkers to prospectively identify these potential responders, such a mechanism is likely to fail in a broad, "all-comers" trial population.

Second, the SLE program highlights the persistent "placebo problem" in autoimmune clinical trials.[35] High response rates in control arms, where patients receive optimized standard of care, create an extremely high bar for demonstrating the incremental benefit of a new agent. This necessitates very large, expensive, and often complex trials to achieve adequate statistical power, a significant barrier to development.

Third, the failure of Efavaleukin alfa does not necessarily invalidate the entire class of IL-2 muteins or the goal of Treg expansion. Instead, it refines the questions for the next generation of these therapies. Future approaches may need to be more sophisticated, perhaps by engineering molecules with greater potency, combining Treg expansion with agents that target other pathogenic pathways, or developing strategies to enhance Treg function and survival within inflamed tissues, not just in circulation.[1]

8.3. Amgen's Portfolio Strategy and R&D Management

From a strategic perspective, the Efavaleukin alfa program demonstrates a mature and disciplined approach to R&D portfolio management. Amgen's investment in an innovative adaptive trial design for the pivotal SLE study, a move endorsed by the FDA's CID Pilot Program, was a key strategic success.[26] While the design could not make an ineffective drug effective, its built-in futility rules enabled the company to obtain a definitive "no" answer efficiently, saving time and resources that would have been spent on a longer, traditional trial.[38]

The decisive termination of programs across four indications reflects a "fail fast" philosophy that is critical for managing the high risks of drug development. The discontinuation of these internal programs should also be viewed in the context of Amgen's broader corporate strategy, which included the major $27.8 billion acquisition of Horizon Therapeutics to significantly bolster its inflammation and rare disease pipeline with approved and late-stage assets.[39] This suggests a strategic pivot, reallocating capital from a high-risk internal mechanism to externally sourced, more de-risked assets. The fact that Amgen's overall R&D spending increased during this period indicates this was a strategic reallocation, not a retreat from the therapeutic area.[39]

8.4. Final Outlook

Efavaleukin alfa will be remembered as a molecule of immense scientific promise that could not bridge the gap to clinical reality. Its journey provides an invaluable case study for immunologists, clinical trialists, and pharmaceutical strategists. It underscores that in the treatment of complex human diseases, an elegant biological mechanism and a potent pharmacodynamic effect are necessary but not always sufficient for success. The lessons learned from its failure—regarding the complexity of autoimmunity, the challenges of clinical trial design, and the importance of disciplined R&D—will undoubtedly inform and guide the development of the next generation of more effective immunomodulatory therapies.

Works cited

1. Cytokine Couture: Designer IL2 Molecules for the Treatment of ..., accessed June 17, 2025, https://www.dovepress.com/article/download/101784
2. Effects of interleukin-2 in immunostimulation and immunosuppression, accessed June 17, 2025, https://rupress.org/jem/article/217/1/e20191247/132567/Effects-of-interleukin-2-in-immunostimulation-and
3. Engineering IL-2 to Give New Life to T Cell Immunotherapy - Annual Reviews, accessed June 17, 2025, https://www.annualreviews.org/doi/pdf/10.1146/annurev-med-073118-011031
4. A glimpse into the application of the immunomodulatory effect of IL-2 in systemic lupus erythematosus - PubMed Central, accessed June 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12055818/
5. AB0432 EFAVALEUKIN ALFA, A NOVEL IL-2 MUTEIN, SELECTIVELY EXPANDS REGULATORY T CELLS IN PATIENTS WITH SLE: FINAL RESULTS OF A PHASE 1B MULTIPLE ASCENDING DOSE STUDY - ResearchGate, accessed June 17, 2025, https://www.researchgate.net/publication/361618831_AB0432_EFAVALEUKIN_ALFA_A_NOVEL_IL-2_MUTEIN_SELECTIVELY_EXPANDS_REGULATORY_T_CELLS_IN_PATIENTS_WITH_SLE_FINAL_RESULTS_OF_A_PHASE_1B_MULTIPLE_ASCENDING_DOSE_STUDY
6. IL-2-based approaches to Treg enhancement | Clinical and Experimental Immunology | Oxford Academic, accessed June 17, 2025, https://academic.oup.com/cei/article/211/2/149/6833176
7. OP0140 REGULATORY T CELL DEFECTS IN SLE AND THERAPY WITH A NOVEL IL-2 MUTEIN: PHASE 1 CLINICAL RESULTS WITH EFAVALEUKIN ALFA, accessed June 17, 2025, https://ard.bmj.com/content/82/Suppl_1/92
8. Review - IL-2-based approaches to Treg enhancement - Oxford Academic, accessed June 17, 2025, https://academic.oup.com/cei/article-pdf/211/2/149/49540339/uxac105.pdf
9. Efavaleukin alfa | MedPath, accessed June 17, 2025, https://trial.medpath.com/drug/d0c0624db8db73af/efavaleukin-alfa
10. Editorial theme | Latest updates on cGvHD treatment - GvHD Hub, accessed June 17, 2025, https://gvhdhub.com/medical-information/editorial-theme-or-latest-updates-on-cgvhd-treatment
11. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report - PMC, accessed June 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8934187/
12. Efavaleukin Alfa, a Novel IL-2 Mutein, Selectively Expands Regulatory T Cells in Patients with SLE: Interim Results of a Phase 1b Multiple Ascending Dose Study - ACR Meeting Abstracts, accessed June 17, 2025, https://acrabstracts.org/abstract/efavaleukin-alfa-a-novel-il-2-mutein-selectively-expands-regulatory-t-cells-in-patients-with-sle-interim-results-of-a-phase-1b-multiple-ascending-dose-study/
13. Efavaleukin alfa - Amgen - AdisInsight - Springer, accessed June 17, 2025, https://adisinsight.springer.com/drugs/800045103
14. Efavaleukin alfa: Uses, Interactions, Mechanism of Action ..., accessed June 17, 2025, https://go.drugbank.com/drugs/DB16149
15. go.drugbank.com, accessed June 17, 2025, https://go.drugbank.com/drugs/DB16149#:~:text=Efavaleukin%20alfa%20is%20a%20fusion,way%20of%20a%20G4S%20linker.
16. EFAVALEUKIN ALFA - Inxight Drugs, accessed June 17, 2025, https://drugs.ncats.io/substance/YNH9K62UXU
17. Efavaleukin alfa (AMG592) | Humanized Antibody - MedchemExpress.com, accessed June 17, 2025, https://www.medchemexpress.com/efavaleukin-alfa.html
18. efavaleukin alfa — TargetMol Chemicals, accessed June 17, 2025, https://www.targetmol.com/search?keyword=efavaleukin%20alfa
19. AB0432 EFAVALEUKIN ALFA, A NOVEL IL-2 MUTEIN ..., accessed June 17, 2025, https://ard.bmj.com/content/81/Suppl_1/1343.3
20. en.wikipedia.org, accessed June 17, 2025, https://en.wikipedia.org/wiki/Efavaleukin_alfa#:~:text=Efavaleukin%20alfa%20is%20an%20experimental,systemic%20lupus%20erythematosus%20(SLE).
21. Efavaleukin alfa - Wikipedia, accessed June 17, 2025, https://en.wikipedia.org/wiki/Efavaleukin_alfa
22. Amg 592 Is an Investigational IL-2 Mutein That Induces Highly Selective Expansion of Regulatory T Cells - ResearchGate, accessed June 17, 2025, https://www.researchgate.net/publication/350672848_Amg_592_Is_an_Investigational_IL-2_Mutein_That_Induces_Highly_Selective_Expansion_of_Regulatory_T_Cells
23. PS7:135 Amg 592 is an investigational il-2 mutein that induces highly selective expansion of regulatory t cells - ResearchGate, accessed June 17, 2025, https://www.researchgate.net/publication/341247928_PS7135_Amg_592_is_an_investigational_il-2_mutein_that_induces_highly_selective_expansion_of_regulatory_t_cells
24. PS7:135 Amg 592 is an investigational il-2 mutein that induces highly selective expansion of regulatory t cells | Lupus Science & Medicine, accessed June 17, 2025, https://lupus.bmj.com/content/5/Suppl_1/A102.1
25. Efavaleukin alfa Drug Profile - Ozmosi, accessed June 17, 2025, https://pryzm.ozmosi.com/product/19285
26. Amgen Announces Participation Of Systemic Lupus Erythematosus (SLE) Adaptive Clinical Trial In The FDA Complex Innovative Trial Designs (CID) Pilot Program, accessed June 17, 2025, https://investors.amgen.com/news-releases/news-release-details/amgen-announces-participation-systemic-lupus-erythematosus-sle/
27. Amgen Announces Participation Of Systemic Lupus Erythematosus (SLE) Adaptive Clinical Trial In The FDA Complex Innovative Trial Designs (CID) Pilot Program - PR Newswire, accessed June 17, 2025, https://www.prnewswire.com/news-releases/amgen-announces-participation-of-systemic-lupus-erythematosus-sle-adaptive-clinical-trial-in-the-fda-complex-innovative-trial-designs-cid-pilot-program-301160908.html
28. Clinical Trial of AMG 592 Administered Subcutaneously - NHS Health Research Authority, accessed June 17, 2025, https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/clinical-trial-of-amg-592-administered-subcutaneously/
29. PO.6.127 Efavaleukin alfa, a novel IL-2 mutein, selectively expands regulatory t cells in patients with SLE: final results of a phase 1b multiple ascending dose study - ResearchGate, accessed June 17, 2025, https://www.researchgate.net/publication/363911440_PO6127_Efavaleukin_alfa_a_novel_IL-2_mutein_selectively_expands_regulatory_t_cells_in_patients_with_SLE_final_results_of_a_phase_1b_multiple_ascending_dose_study
30. Efavaleukin alfa Completed Phase 1 Trials for Systemic Lupus Erythematosus Basic Science | DrugBank Online, accessed June 17, 2025, https://go.drugbank.com/drugs/DB16149/clinical_trials?conditions=DBCOND0027960&phase=1&purpose=basic_science&status=completed
31. Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efavaleukin Alfa in Participants with Systemic Lupus Erythematosus - AmgenTrials, accessed June 17, 2025, https://www.amgentrials.com/study/?id=20170103
32. Product: Efavaleukin Alfa Protocol Number: 20200234 Date: 06 March 2023 Page 1 of 118 CONFIDENTIAL FORM-495569, v.26, 29 May 2020 - ClinicalTrials.gov, accessed June 17, 2025, https://cdn.clinicaltrials.gov/large-docs/37/NCT04680637/Prot_000.pdf
33. Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus - AmgenTrials, accessed June 17, 2025, https://www.amgentrials.com/study/?id=20200234
34. EU Clinical Trials Register, accessed June 17, 2025, https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003509-72/ES
35. When Placebo Plus Standard of Care Clouds the Signal: Unmasking the “Placebo Problem” in Lupus Clinical Trials - Pharmacy Times, accessed June 17, 2025, https://www.pharmacytimes.com/view/when-placebo-plus-standard-of-care-clouds-the-signal-unmasking-the-placebo-problem-in-lupus-clinical-trials
36. Improving resource utilisation in SLE drug development through innovative trial design - Lupus Science & Medicine, accessed June 17, 2025, https://lupus.bmj.com/content/lupusscimed/10/2/e000890.full.pdf
37. Improving resource utilisation in SLE drug development through innovative trial design, accessed June 17, 2025, https://www.researchgate.net/publication/372645052_Improving_resource_utilisation_in_SLE_drug_development_through_innovative_trial_design
38. Improving resource utilisation in SLE drug development through innovative trial design, accessed June 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10373732/
39. Amgen cuts lupus programs for futility - Fierce Biotech, accessed June 17, 2025, https://www.fiercebiotech.com/biotech/amgen-discontinues-rd-work-lupus-futility-reasons
40. Amgen Cuts Lupus Programs Along with Lilly - Life Sciences Voice, accessed June 17, 2025, https://lifescivoice.com/amgen-cuts-lupus-programs-along-with-lilly/
41. 1 National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disea - NCI at Frederick, accessed June 17, 2025, https://ncifrederick.cancer.gov/events/conferences/sites/default/files/inline-files/WG2b_Final_Draft_10_28_2020.pdf
42. A Phase 1b/2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 592 in Adult Subjects With Steroid Refractory Chronic Graft versus Host Disease | Dana-Farber Cancer Institute, accessed June 17, 2025, https://www.dana-farber.org/clinical-trials/18-700
43. A Study to Evaluate the Safety and Effectiveness of AMG 592 in ..., accessed June 17, 2025, https://www.mayo.edu/research/clinical-trials/cls-20449885
44. Product: Efavaleukin Alfa Protocol Number: 20160283 Date: 22 June 2021 Page 1 of 148 - ClinicalTrials.gov, accessed June 17, 2025, https://cdn.clinicaltrials.gov/large-docs/27/NCT03422627/Prot_000.pdf
45. EFAVALEUKIN ALFA - Inxight Drugs - ncats, accessed June 17, 2025, https://drugs.ncats.io/drug/YNH9K62UXU
46. FDA grants drug orphan designation for GVHD | MDedge - The Hospitalist, accessed June 17, 2025, https://blogs.the-hospitalist.org/content/fda-grants-drug-orphan-designation-gvhd
47. Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma, accessed June 17, 2025, https://investor.alkermes.com/news-releases/news-release-details/alkermes-announces-fda-orphan-drug-designation-nemvaleukin-alfa/
48. A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis | Research with human participants, accessed June 17, 2025, https://onderzoekmetmensen.nl/en/trial/54105
49. A Phase 2 Long-Term Extension (LTE) Study to Evaluate The Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis - Onderzoek met mensen, accessed June 17, 2025, https://onderzoekmetmensen.nl/en/node/56326/pdf
50. Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis | Clinical Research Trial Listing - CenterWatch, accessed June 17, 2025, https://www.centerwatch.com/clinical-trials/listings/NCT04987307/safety-and-efficacy-of-efavaleukin-alfa-in-participants-with-moderately-to-severely-active-ulcerative-colitis
51. Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis - ClinicalTrials.Veeva, accessed June 17, 2025, https://ctv.veeva.com/study/safety-and-efficacy-of-efavaleukin-alfa-in-participants-with-moderately-to-severely-active-ulcerativ
52. NCT04987307: An ongoing trial by Amgen - FDAAA Trials Tracker, accessed June 17, 2025, https://fdaaa.trialstracker.net/trial/NCT04987307/
53. Efavaleukin Alfa Treatment for People with Ulcerative Colitis | Rush, accessed June 17, 2025, https://www.rush.edu/clinical-trials/efavaleukin-alfa-treatment-people-ulcerative-colitis
54. Long-term Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis | Clinical Research Trial Listing - CenterWatch, accessed June 17, 2025, https://www.centerwatch.com/clinical-trials/listings/NCT05672199/long-term-safety-and-efficacy-of-efavaleukin-alfa-in-participants-with-moderately-to-severely-active-ulcerative-colitis
55. Long-term Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis - ClinicalTrials.Veeva, accessed June 17, 2025, https://ctv.veeva.com/study/long-term-safety-and-efficacy-of-efavaleukin-alfa-in-participants-with-moderately-to-severely-active
56. Absent of an obesity update, Amgen culls pipeline - FirstWord Pharma, accessed June 17, 2025, https://firstwordpharma.com/story/5908609
57. Protocol - ClinicalTrials.gov, accessed June 17, 2025, https://cdn.clinicaltrials.gov/large-docs/33/NCT04987333/Prot_000.pdf